创新药物融资

Search documents
美银证券:料药明康德(02359)继续抢占市场份额 升目标价至123港元
智通财经网· 2025-08-05 08:11
Group 1 - Bank of America Securities raised the long-term revenue forecast for WuXi AppTec (02359, 603259.SH), adjusting the compound annual growth rate of earnings per share from 2025 to 2032 to 16.2% [1] - The target price for WuXi AppTec's Hong Kong stock was increased from HKD 115.7 to HKD 123, and the A-share target price was raised from RMB 107.6 to RMB 114.4, maintaining a "Buy" rating due to robust order growth and improved operational efficiency [1] - In the first half of the year, the total value of licensing transactions in China's biotechnology and pharmaceutical industry surged by 135% year-on-year to USD 60 billion, indicating a strong market trend [1] Group 2 - Bank of America also raised long-term revenue forecasts for Zai Lab (06127, 603127.SH) and Fonda Holdings (01521) due to improved demand outlook [2] - However, the industry leader WuXi AppTec is expected to continue gaining market share due to its integrated platform and strong operational efficiency, leading to a preference for WuXi AppTec over Zai Lab and Fonda Holdings, which maintain an "Underperform" rating [2] - The target price for Zai Lab's Hong Kong stock was increased from HKD 9.3 to HKD 11, and the A-share target price was raised from RMB 8.5 to RMB 10.1, while Fonda Holdings' target price was adjusted from HKD 0.8 to HKD 0.95 [2]